 Molecular Partners AG NASDAQ: MOLN has announced that a planned futility analysis of ensovibep in the Phase 3 ACTIV-3 study has not met the thresholds required to continue enrollment of hospitalized adults with COVID-19. The independent Data and Safety Monitoring Board DSMB recommends discontinuing recruitment in the ensovibep arm of the ACTIV-3 study conducted by the National Institutes of Health NIH. 